16 Feb 2018
Teleconference Recordings: Fighting for Universal Access To Dolutegravir (DTG)!
On Friday, 2 March 2018 GNP+ hosted two treatment access teleconferences on accelerating the roll out of Dolutegravir, a groundbreaking alternative for first-line HIV regimens. Speakers included: Solange Baptiste, Executive Director, International Treatment Preparedness Coalition (ITPC), Dr. Meg Doherty, Coordinator of Treatment and Care, HIV Department, World Health Organization (WHO), Dr. Gottfried Hirnschall, Director, HIV Department, World Health Organization (WHO), Leena Menghaney, Regional Head Médecins Sans Frontières (MSF) Access Campaign South Asia, Jessica Burry, Pharmacist, Médecins Sans Frontières, Luckyboy Edison Mkhondwane, National Prevention and Treatment Literacy Training Coordinator, Treatment Action Campaign (TAC), Sergey Kondratyuk, Legal Specialist, All Ukrainian Network of People Living with HIV and Sasha Volgina, Program Director, GNP+
Research has shown that the use of Dolutegravir as part of combination therapy results in fewer side effects and more effective suppression of viral load than any integrase inhibitors on the market. Speakers on the teleconferences addressed economic and programmatic implications of DTG rollout in low and middle income countries and will highlight key community strategies, arguments and deliberations impacting the transition and scale up of DTG for people living with HIV. They also spoke about the latest WHO treatment guidelines on DTG, the ongoing clinical research questions regarding DTG use in children, pregnant women and people coinfected with TB and HIV as well as ongoing community concerns over the growing viral resistance to ARVs.
If you didn’t get a chance to participate in the webinars, you can check out the recordings below. Additionally, if you are interested in any of the slide sets that the presenters used please send an email to CJervis@gnpplus.net
First Teleconference Recording – CLICK HERE
Second Teleconference Recording – CLICK HERE